NCT03329950: A Study of CDX-1140 in Patients With Advanced Solid Tumors

NCT03329950
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Active, untreated central nervous system metastases
https://ClinicalTrials.gov/show/NCT03329950

Comments are closed.

Up ↑